PRESENTATION

Q4 2021 — Presentation

Q4 2021PDF · 38 pages2.4 MB
Merck
Q4 2021 Earnings
February 3, 2022

-- 1 of 38 --

Agenda
2
Strategy and
Business Update
Rob Davis
President & Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 38 --

Forward-looking statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
3
This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will
receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability
to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).

-- 3 of 38 --

Strategy &
Business Update
Rob Davis
President & Chief Executive Officer

-- 4 of 38 --

Delivered on our key strategic priorities in 2021
5
Achieved strong commercial and
financial performance
Advanced the pipeline to meet patient
unmet need
Executed on strategic business
development to enhance pipeline
Created long-term value for patients
and shareholders

-- 5 of 38 --

2019 	2020 	2021
$41.5B
+6%
$48.7B
+17%
$39.1B*
2019 	2020 	2021
$4.53
+21%
$6.02
+33%
$3.73*
Full Year Revenue
Full Year EPS
Exceptional Q4 and 2021 sales and earnings growth1
6
$13.5B
+24%
* Growth rate not available as restated 2018 results are not provided.
1. Results from continuing operations attributable to Merck & Co., Inc.
Q4 Worldwide Sales
$1.80
+84%
Q4 Non-GAAP EPS

-- 6 of 38 --

Expect continued strong growth in revenue and earnings
7
10%
15%
20%
25%
30%
35%
40%
45%
2019 	2020 	2021 	2022 	2025
$20
$25
$30
$35
$40
$45
$50
$55
$60
2019 	2020 	2021 	2022 	2025	… 	…
Revenue
Delivering visible de-risked revenue growth
through 2025
Operating margins1
Commitment to drive leverage in the P&L with
operating margins >43% by 2025
2021+ not to scale.
1. Non-GAAP operating margins
$ in billions

-- 7 of 38 --

Multiple levers to navigate the KEYTRUDA LOE
8
• 	Leverage leadership in oncology
• 	Enhance durable growth drivers
• 	Deploy cash flow from key assets
to business development
• 	Advance pipeline across key
therapeutic areas
Shorten period
to return to
strong growth
Minimize
the LOE
gap
Chart not to scale.
Time
Revenue

-- 8 of 38 --

Business development remains an important strategic priority
9
$34.0B
on business development
transactions over
the past 4 years
$3.3B in 2018
$6.1B in 2019
$10.6B in 2020
$14.0B in 2021
Includes bolt-on acquisitions,
strategic collaborations & licensing,
and milestone payments
• 	Accessing the best external
science through value-enhancing
business development
• 	Financial flexibility to pursue
both early- and late-stage
opportunities
• 	Unbounded by therapeutic area
• 	Appropriately aggressive in
adding innovative assets to help
drive long-term revenue growth

-- 9 of 38 --

ESG Priority Areas
Made progress towards integrating ESG into our strategy
10
Access to
health Employees
Environmental
sustainability
Ethics
& values
• 	Inaugural issuance of $1 billion
sustainability bond
• 	Agreement with UNICEF to help
ensure broad global access for
molnupiravir
• 	Hosting ESG Investor Event on
February 23, 2022

-- 10 of 38 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 11 of 38 --

Merck achieved exceptional 2021 financial performance 1
12
WORLDWIDE SALES2
$48.7B+17% growth
+16% ex-exchange
NON-GAAP EPS3,4
$6.02+33% growth
+32% ex-exchange
Merck
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue; 3. Merck is providing certain 2021 and 2020 non-GAAP information that
excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results and permits investors to understand how management assesses performance. Management uses these measures
internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in
part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. 4. GAAP
EPS of $1.51.

-- 12 of 38 --

Strong Q4 sales growth across Human Health and Animal Health
13
Merck
WORLDWIDE SALES1,2
$13.5B+ 24% growth
+23% ex-exchange
+14% ex-exchange, molnupiravir 3
$12.0B
+23% growth
+23% ex-exchange
+13% ex-exchange, molnupiravir 3
Human Health
$1.3B
+8% growth
+8% ex-exchange
Animal Health
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue 3. Excludes impact of foreign exchange and molnupiravir sales of
$952M in the quarter

-- 13 of 38 --

Oncology: KEYTRUDA drives continued momentum
14	Growth rates exclude the impact of foreign exchange.
• KEYTRUDA sales of $4.6B increased 16%
year-over-year, driven by momentum across
key tumor types and recent launches
– In the U.S., sales of $2.7B driven by growth across
all key tumor types, including continued
leadership in lung, as well as TNBC, RCC, HNSCC
and MSI-H
– Ex-U.S., 12% growth was driven by global uptake
in lung as well as RCC and HNSCC
• KEYTRUDA will continue to expand into earlier
lines of therapy
– Recent approvals in adjuvant RCC and Stage IIB or
IIC melanoma, top-line results in NSCLC
– In the U.S., more than half of KEYTRUDA’s annual
growth will come from indications in earlier-stage
treatment settings through 2025, and will
represent roughly 30% of total U.S. KEYTRUDA 4Q19 	4Q20 	4Q21
$4.0B
$3.1B
$4.6B
+27%
+46%
+16%

-- 14 of 38 --

Oncology: Strong growth across broad portfolio
• Lynparza sales increased 33%, with growth
driven by advanced breast and continued
uptake in other approved indications, including
advanced prostate
• Lenvima sales grew 31% driven by RCC and
endometrial in the U.S.
• WELIREG launching successfully in patients
with certain VHL-associated tumors; potential
to expand to broader RCC indications in the
future
Growth rates exclude the impact of foreign exchange.
4Q19 	4Q20 	4Q21
$206M
$132M
$268M
4Q19 	4Q20 	4Q21
$158M
$124M
$206M
15
+53%
+>100%
+33%
+26%
+73%
+31%

-- 15 of 38 --

Vaccines: GARDASIL benefitting from robust global demand and
improved supply
16
• GARDASIL sales of $1.5B increased 50% year-
over-year driven by strong global demand and
increased supply
– Ex-U.S., growth was driven by robust demand,
increased supply and reallocation of doses
– U.S. impacted by CDC purchase timing, stockpile
replenishment in Q4 2020 and COVID-19 vaccine
prioritization
Increase/decrease in sales exclude the impact of foreign exchange.
4Q19 	4Q20 	4Q21
$998M
$693M
$1.5B
+41%
-16%
+50%

-- 16 of 38 --

Hospital: Strong performance by BRIDION and PREVYMIS
17
• BRIDION sales of $436M increased 24%
year-over-year driven by increased usage of
neuromuscular blockade reversal agents and
BRIDION’s growing share within the class
• Continued uptake of PREVYMIS, driven by
ongoing launches
• ZERBAXA supply reinitiated in Q4 following
voluntary recall
Growth rates exclude the impact of foreign exchange.
4Q19 	4Q20 	4Q21
$355M
$313M
$436M
+13%
+24%
+24%

-- 17 of 38 --

Animal Health: durable growth across portfolio
18
• Animal Health sales increased 8% to $1.3B,
reflecting growth across geographies and
species
– Companion Animal sales increased 26%, driven by
the BRAVECTO parasiticide line of products and
vaccines
– Livestock sales reflect higher demand globally for
poultry and swine products
o 	Sales were relatively flat compared with Q4 2020
due to an extra month of sales recorded in Q4 2020
related to the acquisition of Antelliq
Growth rates exclude the impact of foreign exchange.
4Q19 	4Q20 	4Q21
$1.2B
+6%$1.1B
+10%
$1.3B
+8%

-- 18 of 38 --

Q4 2021 continuing operations non-GAAP financial results summary:
Delivered strong revenue and EPS growth
Q4 2021 	Q4 2020 	Change Change
Ex-FX
Sales 	$13.5 	$10.9 	+24% 	+23%
Non-GAAP Gross
Margin1 74.8% 	75.0% 	-0.2pts 	-0.8pts
Operating Expenses 	$5.3 	$5.2 	+2% 	+3%
Tax Rate 	4.3% 	15.3% 	-11.0pts 	N/A
Non-GAAP EPS that
excludes certain items 1 $1.80 	$0.98 	+84% 	+82%
$ in billions, except EPS amounts
19
1. Merck is providing certain 2021 and 2020 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand how management assesses performance.
Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual
compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

-- 19 of 38 --

Merck full-year 2022 guidance
1. GAAP Gross Margin Rate: ~68%. 2. GAAP Operating Expenses: Lower than 2021 by a low to mid-single-digit rate. 3. GAAP Tax Rate: ~12.0% - 13.0%
4. The GAAP to non-GAAP reconciliation is available in Merck’s Q4 2021 earnings release
Guidance 	Key Assumptions
Revenue $56.1B to $57.6B
+15% to +18% (+17% to +20% ex-FX)
• 	Assumes ~2% negative FX impact
• 	Includes an expected $5-6 billion of molnupiravir revenue
Non-GAAP
Gross Margin Rate1 	~74.0% 	• 	Impacted by inclusion of molnupiravir profit share
Non-GAAP
Operating Expenses 2 	Increase by mid-to-high single-digit rate • 	Includes a full year of R&D expenses as a result of the Acceleron
acquisition; investments in portfolio and pipeline
Other (Income) / Expense 	~$350M of expense
Tax Rate3 	~13.0-14.0% • 	Reflects impact of increased molnupiravir revenues and certain tax
legislation changes for research and development expenses in 2022
Shares Outstanding 	~2.53B
GAAP EPS4 	$5.76 to $5.91
Non-GAAP EPS4 	$7.12 to $7.27
+18% to +21% (+19% to +22% ex-FX) • 	Assumes ~1% negative FX impact
20

-- 20 of 38 --

Molnupiravir can be an important treatment option to combat
ongoing global pandemic
21
• 	Revenue guidance range of $5B to $6B in 2022,
weighted to the first half of the year
• 	Obtained 10 regulatory authorizations/approvals,
including EUA from the FDA in December
• 	Announced a number of supply and purchase
agreements totaling ~10M courses of therapy;
broad access strategy for low- and middle-income
countries
• 	Within the next few days, will have shipped >4M
courses of therapy to >25 countries, including ~3M
courses to the U.S.
• 	Share global profits equally with partner Ridgeback
Biotherapeutics

-- 21 of 38 --

Key modeling assumptions & outlook
22
Oncology 	Pneumococcal	GARDASIL 	Animal Health
• 	Strong growth across
oncology portfolio • 	Expect pneumococcal
franchise to grow in 2022
• 	Uptake from recent
launch of VAXNEUVANCE
partially offset by
PNEUMOVAX23 as the
market shifts toward
newer pneumococcal
conjugate vaccines
• 	Very strong growth
driven by robust demand
and increased supply in
2022, albeit not at the
same pace as in 2021
• 	Global HPV vaccination
levels remain low in
eligible patient cohort
• 	Sales to potentially
double by 2030
• 	Above market growth in
2022
• 	Normalization of
favorable companion
animal trends

-- 22 of 38 --

Higher Q4 business development spend driven by Acceleron acquisition
23
Well positioned balance
sheet with capacity to
fund additional
value-enhancing
business development
opportunities
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
$ Billions 1
Capital allocation order of priority
$2.6
$1.2
$1.6
$11.5
$0.0
2
1. Reflects Q4 spend 2. Includes payment for Acceleron acquisition

-- 23 of 38 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 24 of 38 --

Driving value for patients and shareholders by
progressing our pipeline in 2021
25
Oncology
Key regulatory milestones 	Data and pipeline milestones
• 	In the U.S. received 11 FDA approvals1, 1 NME
(WELIREG). FDA accepted filing for KN-158 and
granted priority review for OlympiA
• 	In the EU, received 6 approvals2 and Q6W dosing
regimen for KEYTRUDA. Received CHMP positive
opinion for KN-361 and KN-5642
• 	In Japan, received 5 approvals
• 	In China, received 3 approvals and Q6W dosing
regimen for KEYTRUDA
• 	In the U.S., received FDA approval for
VAXNEUVANCE in the adult setting. FDA
granted priority review for VAXNEUVANCE in the
pediatric setting
• 	In the EU, received CHMP positive opinion for
VAXNEUVANCE in the adult setting
• 	Received FDA Emergency Use Authorization for
molnupiravir as well as authorization in other
markets
• 	In Japan, received approval for LYFNUA
(gefapixant3) and RECARBRIO
• 	Verquvo received approvals in the U.S., EU and
Japan
Infectious diseases,
cardiometabolic &
new products
Vaccines
• Presented new data and announced topline
results for assets across our broad portfolio,
including KN-091 and PROpel
• Advanced novel mechanisms including
coformulations with pembrolizumab into Phase 3:
• vibostolimab+pembrolizumab (TIGIT)
• quavonlimab+pembrolizumab (CTLA-4)
• favezelimab+pembrolizumab (LAG3)
• Presented new data for MK-0616 (oral PCSK9)
• Advanced pipeline assets MK-2060 (Factor XI
inhibitor), MK-5475 (inhaled SGC) and Verquvo
• Advanced molnupiravir in post-exposure
prophylaxis for COVID-19
• Acquired new assets through business
development, including MK-6194 (IL-2 mutein)
and sotatercept (ligand trap)
• Announced topline results from Phase 3 trials
for VAXNEUVANCE (i.e.: PNEU-PED)
30
Approvals
20
NDAs and
sBLAs filed
In US, EU, Japan and
China in 2021, more
than:
1.Reflects new approvals and conversions to full approvals 2. Received European Commission approval for KN-564 in
January 2022 3. Received Ministry of Health, Labor and Welfare approval in January 2022

-- 25 of 38 --

Molnupiravir represents an important treatment option
against COVID-19 in high-risk, non-hospitalized patients
26
• 	Pandemic continues to impact communities
and health care systems
• 	Accessible therapeutic options are needed
for high-risk patients
• 	Six independent preclinical studies
demonstrated molnupiravir showed activity
against Omicron variant in vitro
• 	Molnupiravir is well-positioned to play a role
due to its key attributes:
– Oral treatment option
– Reduction in hospitalizations or deaths in
MOVe-OUT trial, including ~90% fewer deaths
– Low propensity for drug-drug interactions
– Activity against Omicron in vitro
– High barrier to resistance
Early treatment with molnupiravir reduced the
risk of hospitalization or death in at-risk,
unvaccinated adults with Covid-19.
This study has demonstrated that molnupiravir
… potently inhibited the infection of SARS-
CoV-2 Omicron variant.

-- 26 of 38 --

Continuing to make progress with the broadest early-stage
IO clinical development program
27
• 	Recent approvals in RCC and melanoma
‒ KEYTRUDA is the first and only immunotherapy
treatment option in the adjuvant RCC setting
‒ KEYTRUDA is first and only anti-PD1 therapy
approved as adjuvant treatment in melanoma
across stages IIB, IIC and III disease
• 	Announced findings in NSCLC
• 	Priority review in early-stage, high-risk
breast cancer

-- 27 of 38 --

Pipeline updates and progress
28
HIV	Chronic Cough 	Cardiometabolic	Pneumococcal Disease
1. On clinical hold
• 	Discuss next steps with
the FDA for gefapixant
• 	Committed to
addressing significant
unmet need
• 	Received approval for
LYFNUA (gefapixant) in
Japan
• 	VAXNEUVANCE
approved for adults in
U.S. and EU
• 	Under priority review by
the FDA in the pediatric
setting
• 	Continue to evaluate
data in studies with
islatravir 1
• 	Confident in the
potential of the NRTTI
mechanism for
prevention and
treatment of HIV
• 	Completed acquisition of
Acceleron with ongoing
integration
• 	Phase 3 program
studying sotatercept for
pulmonary arterial
hypertension on track

-- 28 of 38 --

34%
24%
23%
13%
6%
Extensive research efforts across multiple
therapeutic areas and modalities
29
• 	Become the leading oncology
company by 2025 and ensure that
position is durable beyond
• 	Extend our impact across
cardiometabolic, immunology,
infectious diseases, neuroscience
and vaccines
• 	Advance internal pipeline and
augment with external assets
Executing on our strategy to:
% of programs per area
Programs under other research areas are included within above categories
>120
discovery & early
development
programsOncology
Neuroscience
ID/Vaccines
Immunology
Cardiometabolic
Disease

-- 29 of 38 --

Q&A
Rob Davis
President & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Vice President, Investor Relations

-- 30 of 38 --

Appendix
31

-- 31 of 38 --

Q4 2021 continuing operations GAAP financial results summary:
32
Q4 2021 	Q4 2020 	Change Change
Ex-FX
Sales 	$13.5 	$10.9 	+24% 	+23%
Operating Expenses 	$5.9 	$8.4 	-30% 	-30%
Tax Rate 	2.2% 	-2.7% 	+4.9% 	N/A
GAAP EPS 	$1.51 	($1.03) 	+>100% 	+>100%
$ in billions, except EPS amounts

-- 32 of 38 --

2021 continuing operations GAAP financial results summary:
33
2021 	2020 	Change Change
Ex-FX
Sales 	$48.7 	$41.5 	+17% 	+16%
Operating Expenses 	$21.9 	$22.4 	-2% 	-3%
Tax Rate 	11.0% 	22.9% 	-11.9pts 	N/A
GAAP EPS 	$4.86 	$1.78 	+>100% 	+>100%
$ in billions, except EPS amounts

-- 33 of 38 --

2021 continuing operations non-GAAP financial results summary:
Delivered strong revenue and EPS growth
2021 	2020 	Change Change
Ex-FX
Sales 	$48.7 	$41.5 	+17% 	+16%
Non-GAAP Gross
Margin1 76.1% 	76.3% 	-0.2pts 	-0.3pts
Operating Expenses 	$19.4 	$17.7 	+9% 	+8%
Tax Rate 	11.2% 	15.2% 	-4.0pts 	N/A
Non-GAAP EPS that
excludes certain items 1 $6.02 	$4.53 	+33% 	+32%
$ in billions, except EPS amounts
34
1. Merck is providing certain 2021 and 2020 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying
business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand how
management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other
metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute
for or superior to, information prepared in accordance with GAAP.

-- 34 of 38 --

2021: key pillars driving strong growth over the past four years1
1. All growth rates exclude the impact of foreign exchange 2. In millions 35
2018 	2019 	2020 	2021
$11,084
KEYTRUDA Performance
2018 	2019 	2020 	2021
Lynparza Performance
2018 	2019 	2020 	2021
Lenvima Performance
2018 	2019 	2020 	2021
Animal Health Performance
2018 	2019 	2020 	2021
GARDASIL Performance
2018 	2019 	2020 	2021
BRIDION Performance
$7,171
$14,380
$17,186
$187
$725
$444
$149
$404
$580
$4,703
$4,393
$4,212
$5,568
$3,151
$3,737 $3,938
$5,673
$1,131 $1,198
$917
$1,532
$704
+16% YOY 	+39% YOY
+27% YOY
+20% YOY
+35% YOY
+18% YOY
$989

-- 35 of 38 --

$8.9
$4.5
$6.6
$14.0
$0.8
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$ 20B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
Billions
$1.72 	$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$2.60
$2.76
$1.40
$1.70
$2.00
$2.30
$2.60
$2.90
2013 	2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021 	2022E
Dollars per share	
+11% 	+2% 	+2% 	+2% 	+2% 	+2%
+11%
+15%
+7%
Order of priority
Over the past 12 months
Capital investments
2021 to 2025
Commitment to the dividend
36
Well positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
+6%

-- 36 of 38 --

Driving value for patients and shareholders by progressing our pipeline
37
Key regulatory milestones
since the last earnings call:
Key data and presentations
since the last earnings call:
• 	In the U.S., received approval for KEYTRUDA
as adjuvant therapy for certain patients with
RCC based on KN-564 and as adjuvant
treatment for patients with stage IIB and IIC
melanoma based on KN-716
• 	Received FDA Emergency Use Authorization
for molnupiravir as well as authorization in
other markets
• 	FDA granted priority review for
VAXNEUVANCE in the pediatric setting and
for Lynparza in certain early-stage breast
cancers based on OlympiA
• 	In the EU, received approvals for KEYTRUDA
in adjuvant RCC based on KN-564, for
KEYTRUDA+lenvatinib1 in advanced RCC
based on KN-581 and in endometrial cancer
based on KN-775, as well as for
VAXNEUVANCE in adults
• 	In Japan, received approvals for KEYTRUDA
in esophageal cancer based on KN-590 and
endometrial cancer based on KN-775 as well
as gefapixant
• 	Presented data for KEYTRUDA at SMR, SITC
and ASCO GI, for MK-2140 (ROR1-ADC) at ASH,
for molnupiravir at ASTMH, and for MK-0616
(oral PCSK9 inhibitor) at AHA
• 	Initiated Phase 3 trial studying Verquvo in
patients with chronic heart failure and reduced
ejection fraction who have not had a recent
worsening heart failure event
• 	Announced topline results for KEYTRUDA as
adjuvant treatment for patients with NSCLC
based on KN-091
Brand name in Europe is KYSPLIX for RCC and LENVIMA for endometrial	1.

-- 37 of 38 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V116
Pneumococcal, adult
V184
Chikungunya Virus
Vaccines
Infectious diseases
MK-8189
Schizophrenia
Neuroscience
Gefapixant (MK-7264)
Cough (US, EU)
CUBICIN (MK-3009)
cSST & Sepsis, pediatric (JPN)
General medicine	General medicine
As of February 2, 2022
V114
Pneumoconjugate Vaccine, adult (JPN),
pediatric (US)
Vaccines
Infectious diseases
Oncology 	Oncology
MK-7075
Overgrowth Syndrome
MK-1942
Treatment Resistant Depression
MK-3655
NASH
MK-6024
NASH
MK-8591B (islatravir/MK-8507)1
HIV-1 Infection
MK-8591D (islatravir/lenacapavir)1
HIV-1 Infection
KEYTRUDA (MK-3475)
Biliary Tract
cSCC (EU)
Gastric (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
Prostate
SCLC
MK-1308A
RCC
MK-7684A
NSCLC
MK-4280A
CRC
LENVIMA (MK-7902)
HNSCC
Melanoma
CRC
Esophageal
NSCLC
Gastric
LYNPARZA (MK-7339)
NSCLC
SCLC
CRC
WELIREG (MK-6482)
RCC
TUKYSA (MK-7119)
Breast
MK-3475 subcutaneous
NSCLC
MK-8591A (doravirine/islatravir)1
HIV-1 Infection
Islatravir (MK-8591)1
HIV-1 prevention
KEYTRUDA (MK-3475)
MSI-H or dMMR Endometrial (US)
TMB-H (JPN)
Adjuvant RCC (JPN)
Melanoma (EU)
High-risk early stage TNBC (EU, JPN)
Cervical (EU, JPN)
LENVIMA (MK-7902)
1L HCC (US)
Advanced unresectable RCC (JPN)
LYNPARZA (MK-7339)
Prostate cancer (EU)
Adjuvant breast cancer (US, EU)
MK-5475
Pulmonary Arterial Hypertension
MK-2060
Cardiovascular
Cardiovascular
KEYTRUDA (MK-3475)
Advanced Solid Tumors
LYNPARZA (MK-7339)
Advanced Solid Tumors
MK-6440
(ladiratuzumab vedotin)
Breast
NSCLC
SCLC
HNSCC
Esophageal
Gastric
Prostate
Melanoma
MK-1026
Hematological Malignancies
V937
Melanoma
Breast
CSCC
HNSCC
Solid Tumors
MK-4280A
(favezelimab/pembrolizumab)
RCC
SCLC
WELIREG (MK-6482)
Rare Cancers
CRC
Pancreatic
Biliary
HCC
Certain VHL tumors (EU)
MK-4280
(favezelimab)
NSCLC
Hematological Malignancies
LENVIMA (MK-7902)
Biliary Tract
Glioblastoma
Prostate
SCLC
Pancreas
MK-7684A
(vibostolimab/pembrolizumab)
Biliary
Cervical
Esophageal
Breast
HNSCC
HCC
Endometrial
Prostate
Hematological Malignancies
MK-1308A
(quavonlimab/
pembrolizumab)
Advanced Solid Tumors
HCC
CRC
SCLC
Melanoma
TUKYSA (MK-7119)
Advanced Solid Tumors
Colorectal
Gastric
Endometrial
NSCLC
Bladder
Biliary
Cervical
MK-2140
Breast
NSCLC
Heme
MK-4830
NSCLC
SCLC
RCC
MK-0482
NSCLC
MK-1308
NSCLC
MK-5890
NSCLC
SCLC
MK-7684
Melanoma
Broad and innovative pipeline to solve significant unmet medical needs
38
Vaccines
MK-1654
Respiratory Syncytial Virus
1. On clinical hold
Sotatercept (MK-7962)
Pulmonary Arterial Hypertension
Cardiovascular

-- 38 of 38 --